280 related articles for article (PubMed ID: 25803170)
1. MDM2 turnover and expression of ATRX determine the choice between quiescence and senescence in response to CDK4 inhibition.
Kovatcheva M; Liu DD; Dickson MA; Klein ME; O'Connor R; Wilder FO; Socci ND; Tap WD; Schwartz GK; Singer S; Crago AM; Koff A
Oncotarget; 2015 Apr; 6(10):8226-43. PubMed ID: 25803170
[TBL] [Abstract][Full Text] [Related]
2. PDLIM7 and CDH18 regulate the turnover of MDM2 during CDK4/6 inhibitor therapy-induced senescence.
Klein ME; Dickson MA; Antonescu C; Qin LX; Dooley SJ; Barlas A; Manova K; Schwartz GK; Crago AM; Singer S; Koff A; Tap WD
Oncogene; 2018 Sep; 37(37):5066-5078. PubMed ID: 29789718
[TBL] [Abstract][Full Text] [Related]
3. Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas.
Laroche-Clary A; Chaire V; Algeo MP; Derieppe MA; Loarer FL; Italiano A
J Hematol Oncol; 2017 Jun; 10(1):123. PubMed ID: 28629371
[TBL] [Abstract][Full Text] [Related]
4. CDK4 inhibition diminishes p53 activation by MDM2 antagonists.
Sriraman A; Dickmanns A; Najafova Z; Johnsen SA; Dobbelstein M
Cell Death Dis; 2018 Sep; 9(9):918. PubMed ID: 30206211
[TBL] [Abstract][Full Text] [Related]
5. Immunoreactivity of p53, mdm2, and p21WAF1 in dedifferentiated liposarcoma: special emphasis on the distinct immunophenotype of the well-differentiated component.
Adachi T; Oda Y; Sakamoto A; Saito T; Tamiya S; Masuda K; Tsuneyoshi M
Int J Surg Pathol; 2001 Apr; 9(2):99-109. PubMed ID: 11484509
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic utility of p16, CDK4, and MDM2 as an immunohistochemical panel in distinguishing well-differentiated and dedifferentiated liposarcomas from other adipocytic tumors.
Thway K; Flora R; Shah C; Olmos D; Fisher C
Am J Surg Pathol; 2012 Mar; 36(3):462-9. PubMed ID: 22301498
[TBL] [Abstract][Full Text] [Related]
7. Overlapping features between dedifferentiated liposarcoma and undifferentiated high-grade pleomorphic sarcoma.
Chung L; Lau SK; Jiang Z; Loera S; Bedel V; Ji J; Weiss LM; Chu PG
Am J Surg Pathol; 2009 Nov; 33(11):1594-600. PubMed ID: 19574885
[TBL] [Abstract][Full Text] [Related]
8. Molecular abnormalities in liposarcoma: role of MDM2 and CDK4-containing amplicons at 12q13-22.
Pilotti S; Della Torre G; Lavarino C; Sozzi G; Minoletti F; Vergani B; Azzarelli A; Rilke F; Pierotti MA
J Pathol; 1998 Jun; 185(2):188-90. PubMed ID: 9713346
[TBL] [Abstract][Full Text] [Related]
9. Histological Classification and Immunohistochemical Evaluation of MDM2 and CDK4 Expression in Canine Liposarcoma.
Avallone G; Roccabianca P; Crippa L; Lepri E; Brunetti B; Bernardini C; Forni M; Olandese A; Sarli G
Vet Pathol; 2016 Jul; 53(4):773-80. PubMed ID: 26993784
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma.
Dickson MA; Tap WD; Keohan ML; D'Angelo SP; Gounder MM; Antonescu CR; Landa J; Qin LX; Rathbone DD; Condy MM; Ustoyev Y; Crago AM; Singer S; Schwartz GK
J Clin Oncol; 2013 Jun; 31(16):2024-8. PubMed ID: 23569312
[TBL] [Abstract][Full Text] [Related]
11. Stromal Senescence By Prolonged CDK4/6 Inhibition Potentiates Tumor Growth.
Guan X; LaPak KM; Hennessey RC; Yu CY; Shakya R; Zhang J; Burd CE
Mol Cancer Res; 2017 Mar; 15(3):237-249. PubMed ID: 28039358
[TBL] [Abstract][Full Text] [Related]
12. Antiproliferative effects of CDK4/6 inhibition in CDK4-amplified human liposarcoma in vitro and in vivo.
Zhang YX; Sicinska E; Czaplinski JT; Remillard SP; Moss S; Wang Y; Brain C; Loo A; Snyder EL; Demetri GD; Kim S; Kung AL; Wagner AJ
Mol Cancer Ther; 2014 Sep; 13(9):2184-93. PubMed ID: 25028469
[TBL] [Abstract][Full Text] [Related]
13. Can MDM2 and CDK4 make the diagnosis of well differentiated/dedifferentiated liposarcoma? An immunohistochemical study on 129 soft tissue tumours.
Aleixo PB; Hartmann AA; Menezes IC; Meurer RT; Oliveira AM
J Clin Pathol; 2009 Dec; 62(12):1127-35. PubMed ID: 19946100
[TBL] [Abstract][Full Text] [Related]
14. Aberrant expression of the cell cycle associated proteins TP53, MDM2, p21, p27, cdk4, cyclin D1, RB, and EGFR in cervical carcinomas.
Skomedal H; Kristensen GB; Lie AK; Holm R
Gynecol Oncol; 1999 May; 73(2):223-8. PubMed ID: 10329038
[TBL] [Abstract][Full Text] [Related]
15. Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib: A Phase 2 Clinical Trial.
Dickson MA; Schwartz GK; Keohan ML; D'Angelo SP; Gounder MM; Chi P; Antonescu CR; Landa J; Qin LX; Crago AM; Singer S; Koff A; Tap WD
JAMA Oncol; 2016 Jul; 2(7):937-40. PubMed ID: 27124835
[TBL] [Abstract][Full Text] [Related]
16. Detection of MDM2/CDK4 amplification in lipomatous soft tissue tumors from formalin-fixed, paraffin-embedded tissue: comparison of multiplex ligation-dependent probe amplification (MLPA) and fluorescence in situ hybridization (FISH).
Creytens D; van Gorp J; Ferdinande L; Speel EJ; Libbrecht L
Appl Immunohistochem Mol Morphol; 2015 Feb; 23(2):126-33. PubMed ID: 25679065
[TBL] [Abstract][Full Text] [Related]
17. TP53 alterations in relation to the cell cycle-associated proteins p21, cyclin D1, CDK4, RB, MDM2, and EGFR in cancers of the uterine corpus.
Skomedal H; Kristensen GB; Nesland JM; Børresen-Dale AL; Tropé C; Holm R
J Pathol; 1999 Apr; 187(5):556-62. PubMed ID: 10398121
[TBL] [Abstract][Full Text] [Related]
18. Clinical and biological significance of CDK4 amplification in well-differentiated and dedifferentiated liposarcomas.
Italiano A; Bianchini L; Gjernes E; Keslair F; Ranchere-Vince D; Dumollard JM; Haudebourg J; Leroux A; Mainguené C; Terrier P; Chibon F; Coindre JM; Pedeutour F
Clin Cancer Res; 2009 Sep; 15(18):5696-703. PubMed ID: 19737942
[TBL] [Abstract][Full Text] [Related]
19. To Quiesce or Senesce, That Is the Question for Dedifferentiated Liposarcoma.
Weiss MC; Eulo V; Van Tine BA
Clin Cancer Res; 2024 Feb; 30(4):649-651. PubMed ID: 38064245
[TBL] [Abstract][Full Text] [Related]
20. HDACi inhibits liposarcoma via targeting of the MDM2-p53 signaling axis and PTEN, irrespective of p53 mutational status.
Ou WB; Zhu J; Eilers G; Li X; Kuang Y; Liu L; Mariño-Enríquez A; Yan Z; Li H; Meng F; Zhou H; Sheng Q; Fletcher JA
Oncotarget; 2015 Apr; 6(12):10510-20. PubMed ID: 25888633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
